[go: up one dir, main page]

WO1999053953A3 - Methodes et produits concernant les interactions metaboliques dans les maladies - Google Patents

Methodes et produits concernant les interactions metaboliques dans les maladies Download PDF

Info

Publication number
WO1999053953A3
WO1999053953A3 PCT/US1999/006874 US9906874W WO9953953A3 WO 1999053953 A3 WO1999053953 A3 WO 1999053953A3 US 9906874 W US9906874 W US 9906874W WO 9953953 A3 WO9953953 A3 WO 9953953A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
disease
products related
metabolic interactions
metabolic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/006874
Other languages
English (en)
Other versions
WO1999053953A2 (fr
Inventor
Martha K Newell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Vermont
Original Assignee
University of Vermont
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Vermont filed Critical University of Vermont
Priority to AU33705/99A priority Critical patent/AU768656B2/en
Priority to EP99915109A priority patent/EP1077724A2/fr
Priority to CA002324995A priority patent/CA2324995A1/fr
Priority to JP2000544356A priority patent/JP2002512203A/ja
Publication of WO1999053953A2 publication Critical patent/WO1999053953A2/fr
Publication of WO1999053953A3 publication Critical patent/WO1999053953A3/fr
Anticipated expiration legal-status Critical
Priority to AU2004201144A priority patent/AU2004201144B2/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)

Abstract

La présente invention concerne des méthodes de régulation de la croissance et de la division cellulaires qui permettent de maîtriser des processus morbides par manipulation du métabolisme mitochondrial et par expression des protéines immunitaires de la surface cellulaire. L'invention concerne également des compositions et des essais de criblage connexes.
PCT/US1999/006874 1998-04-17 1999-03-30 Methodes et produits concernant les interactions metaboliques dans les maladies Ceased WO1999053953A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU33705/99A AU768656B2 (en) 1998-04-17 1999-03-30 Methods and products related to metabolic interactions in disease
EP99915109A EP1077724A2 (fr) 1998-04-17 1999-03-30 Methodes et produits concernant les interactions metaboliques dans les maladies
CA002324995A CA2324995A1 (fr) 1998-04-17 1999-03-30 Methodes et produits concernant les interactions metaboliques dans les maladies
JP2000544356A JP2002512203A (ja) 1998-04-17 1999-03-30 疾患における代謝的相互作用に関連する方法および製品
AU2004201144A AU2004201144B2 (en) 1998-04-17 2004-03-18 Methods and products related to metabolic interactions in disease

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US8225098P 1998-04-17 1998-04-17
US60/082,250 1998-04-17
US9451998P 1998-07-29 1998-07-29
US60/094,519 1998-07-29
US10158098P 1998-09-24 1998-09-24
US60/101,580 1998-09-24

Publications (2)

Publication Number Publication Date
WO1999053953A2 WO1999053953A2 (fr) 1999-10-28
WO1999053953A3 true WO1999053953A3 (fr) 2000-01-13

Family

ID=27374244

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/006874 Ceased WO1999053953A2 (fr) 1998-04-17 1999-03-30 Methodes et produits concernant les interactions metaboliques dans les maladies

Country Status (5)

Country Link
EP (1) EP1077724A2 (fr)
JP (1) JP2002512203A (fr)
AU (1) AU768656B2 (fr)
CA (1) CA2324995A1 (fr)
WO (1) WO1999053953A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381413B1 (en) 1998-04-17 2008-06-03 University Of Vermont And State Agricultural College Methods and products related to metabolic interactions in disease
US6599710B1 (en) * 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
AU780815B2 (en) 1999-06-23 2005-04-21 University Of Vermont And State Agricultural College, The Methods and products for manipulating uncoupling protein expression
US6365796B1 (en) 2000-02-16 2002-04-02 Beth Israel Deaconess Medical Center Transgenic UCP2 knockout mouse and use thereof
US7521047B2 (en) 2000-05-12 2009-04-21 Gpc Biotech Ag Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
US6670138B2 (en) 2000-11-01 2003-12-30 Agy Therapeutics, Inc. Method of diagnosing ischemic stroke via UCP-2 detection
ES2376422T3 (es) 2001-08-21 2012-03-13 Ventana Medical Systems, Inc. Método y ensayo de cuantificación para determinar el estado c-kit/scf/pakt.
WO2005077065A2 (fr) * 2004-02-09 2005-08-25 The Regents Of The University Of California Ligands polyvalents selectifs a haute affinite et methodes de fabrication
NZ574009A (en) * 2006-06-20 2012-01-12 Genentech Inc Methods and materials for observing apoptosis by detecting fragments of clathrin-pathway components
AU2009237577B2 (en) * 2008-04-18 2014-06-05 Baxter Healthcare Sa Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
JP5623384B2 (ja) 2008-04-21 2014-11-12 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 選択的高親和性リガンドおよびこれらを作製する方法
EA201391245A1 (ru) * 2011-03-02 2014-05-30 Берг Ллк Интеррогативные клеточные анализы и их применение
PL2953634T3 (pl) 2013-02-07 2021-11-22 The General Hospital Corporation Sposoby namnażania lub zubożania limfocytów t-regulatorowych
CN105829885B (zh) 2013-10-17 2020-08-18 综合医院公司 鉴定响应于用于自身免疫性疾病的治疗的受试者的方法以及用于治疗该疾病的组合物
EP3163284A4 (fr) * 2014-06-27 2017-06-28 National University Corporation Nagoya University Matériau d'enrobage pour préparation d'échantillon, procédé de préparation d'échantillon non perméable de matériau de base durcissable, procédé de préparation d'échantillon perméable de matériau de base durcissable, échantillon non perméable de matériau de base durcissable, agent améliorant les propriétés de découpe en tranches minces pour agent d'enrobage congelé, et agent d'enrobage congelé
ES2962885T3 (es) 2015-05-15 2024-03-21 Massachusetts Gen Hospital Anticuerpos antagonistas de la superfamilia del receptor del factor de necrosis tumoral
US20190135929A1 (en) 2015-08-28 2019-05-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
WO2017059132A1 (fr) 2015-09-29 2017-04-06 The General Hospital Corporation Méthodes de traitement et de diagnostic d'une maladie à l'aide de biomarqueurs pour thérapie par bcg
KR20250007678A (ko) 2016-05-13 2025-01-14 더 제너럴 하스피탈 코포레이션 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 항체

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998002579A1 (fr) * 1996-07-12 1998-01-22 Emory University Regulation de l'apoptose et modele in vitro destine a des recherches en la matiere

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998002579A1 (fr) * 1996-07-12 1998-01-22 Emory University Regulation de l'apoptose et modele in vitro destine a des recherches en la matiere

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; STREET D ET AL: "Interferon-gamma enhances susceptibility of cervical cancer cells to lysis by tumor-specific cytotoxic T cells.", XP002122832, retrieved from STN Database accession no. 97302905 *
GENESTIER L ET AL: "Caspase-dependent ceramide production in Fas - and HLA class I-mediated peripheral T cell apoptosis.", JOURNAL OF BIOLOGICAL CHEMISTRY, (1998 FEB 27) 273 (9) 5060-6., XP002122830 *
GYNECOLOGIC ONCOLOGY, (1997 MAY) 65 (2) 265-72. *
HERMESH O ET AL: "Mitochondria uncoupling by a long chain fatty acyl analogue.", JOURNAL OF BIOLOGICAL CHEMISTRY, (1998 FEB 13) 273 (7) 3937-42., XP002122831 *
LEE J W ET AL: "HLA-DR-mediated signals for hematopoiesis and induction of apoptosis involve but are not limited to a nitric oxide pathway.", BLOOD, (1997 JUL 1) 90 (1) 217-25., XP002122829 *
SATOH T ET AL: "CHANGES IN MITOCHONDRIAL MEMBRANE POTENTIAL DURING OXIDATIVE STRESS-INDUCED APOPTOSIS IN PC12 CELLS", JOURNAL OF NEUROSCIENCE RESEARCH,US,WILEY-LISS, vol. 50, no. 3, pages 413-420, XP002058714, ISSN: 0360-4012 *
SCAFFIDI C ET AL: "Two CD95 ( APO - 1 / Fas ) signaling pathways.", EMBO JOURNAL, (1998 MAR 16) 17 (6) 1675-87., XP002122827 *
SUMMERFIELD A ET AL: "Lymphocyte apoptosis during classical swine fever: implication of activation-induced cell death.", JOURNAL OF VIROLOGY, (1998 MAR) 72 (3) 1853-61., XP002122828 *

Also Published As

Publication number Publication date
CA2324995A1 (fr) 1999-10-28
JP2002512203A (ja) 2002-04-23
WO1999053953A2 (fr) 1999-10-28
AU3370599A (en) 1999-11-08
AU768656B2 (en) 2003-12-18
EP1077724A2 (fr) 2001-02-28

Similar Documents

Publication Publication Date Title
WO1999053953A3 (fr) Methodes et produits concernant les interactions metaboliques dans les maladies
WO1999042077A3 (fr) Compositions et procedes de regulation de l'activation des lymphocytes
BG101030A (en) Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
WO1999061619A8 (fr) Genes et proteines de cycle cellulaire et leurs utilisations
IL117425A0 (en) Receptor activation by gas6
WO2005003168A3 (fr) Compositions et procedes pour la regulation d'activite de cellules nk
IL133011A0 (en) Method for the production of non-group c adenoviral vectors
HUP9801370A3 (en) Stable protein:phospholipid compositions and methods for production thereof
CA2413156A1 (fr) Vecteurs d'expression
MX9801864A (es) Materiales y metodos con relacion a la union y presentacion de substancias sobre superficies de celulas.
CA2222425A1 (fr) Immortalisation et desimmortalisation de cellules
EP0754229A1 (fr) L'alfamine, une proteine albuminoide serique humaine
IE830945L (en) Process for obtaining permanently culturable animal and¹human cell lines
WO2001004282A3 (fr) Vecteurs anti-cancereux de replication
ZA991707B (en) Methods and compositions for regulating cell death and enhancing disease resistance to plant pathogen.
FR2757505B1 (fr) Procede de production d'isobutene de haute purete combinant une distillation reactive d'hydroisomerisation, une distillation et une isomerisation squelettale
AU2003204353A1 (en) Methods and compositions for enhancing immune response and for the production of in vitro mabs
AU7423391A (en) Dna constructs for the expression of proteins in the mammary gland of transgenetic mammals
DK1000154T3 (da) Identificering af humane cellelinjer til produktion af humane proteiner ved endogen genaktivering
HK1040420A1 (zh) 新陳代謝的選擇方法
CA2201336A1 (fr) Champignon de l'espece gliocladium catenulatum utilise pour la lutte biologique contre les maladies vegetales
WO2000037645A3 (fr) Acides nucleiques intervenant dans le cycle cellulaire, polypeptides et leurs utilisations
EP0754757A3 (fr) Promoteur végétal et son utilisation
AU8045294A (en) Methods for producing protein C
CA2222718A1 (fr) Cellules 293 presentant une faculte de fixation amelioree

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 33705/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2324995

Country of ref document: CA

Ref country code: CA

Ref document number: 2324995

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 544356

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999915109

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999915109

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 33705/99

Country of ref document: AU